CLAIMS

1. Use of olanexidine or a pharmacologically acceptable salt thereof for the manufacture of an agent for ameliorating and/or preventing an inflammation, with the proviso that oral mucositis due to treatment of a cancer is excluded.

2. The use according to claim 1, wherein the olanexidine or the pharmacologically acceptable salt thereof is olanexidine gluconate.

3. The use according to claim 1 or 2, wherein the agent further comprises a poloxamer which is a block copolymer consisting of a chain of polyoxypropylene (POP) and two chains of polyoxyethylene (POE) flanking the POP.

4. The use according to any one of claims 1 to 3, wherein the inflammation is selected from stomatitis, gingivitis, and pneumonia.

5. The use according to claim 3 or 4, wherein the poloxamer is selected from polyoxyethylene (42) polyoxypropylene (67) glycol (Pluronic P-123), polyoxyethylene (54) polyoxypropylene (39) glycol (Pluronic P-85), and polyoxyethylene (196) polyoxypropylene (67) glycol (Pluronic F-127).

6. The use according to claim 5, wherein the poloxamer is polyoxyethylene (42) polyoxypropylene (67) glycol (Pluronic P-123).

7. The use according to any one of claims 1 to 6, wherein a concentration of the olanexidine gluconate is 0.05 to 0.5% (W/V).

8. The use according to any one of claims 3 to 7, wherein a concentration of the poloxamer is 0.1 to 5.0% (W/V).

9. The use according to any one of claims 1 to 8, wherein the agent is in a form of a liquid or a gargle.